CONFERENCE COVERAGE SERIES
Human Amyloid Imaging 2013
Miami, FL, U.S.A.
16 – 18 January 2013
Solanezumab Selected for Alzheimer’s A4 Prevention Trial
Researchers announced the selection of solanezumab as the first therapeutic drug to be evaluated in the A4 prevention clinical trial...
HAI—Spotlight on Tau Tracers at Human Amyloid Imaging Meeting
A group of 250 scientists met at the 7th Human Amyloid Imaging (HAI) meeting to share the most up-to-date research on brain imaging...
HAI—Amyloid Imaging in the Clinic: New Guidelines and Data
Since the FDA approved the Aβ imaging agent florbetapir (Amyvid®) last April, academics and doctors have debated how it should be used...
HAI—Sharper Curves: Revamping a Biomarker Staging Model
Clifford Jack's hypothetical model showing biomarkers emerging at different stages of AD surged to the top of the Most-Popular-Slide-at-Conferences chart...
HAI—Standardizing Amyloid PET: The Centiloid Project
A centiloid is a proposed unit of measure on a unified scale for all amyloid-β imaging tracers used in positron emission tomography (PET)...
HAI—Aβ: First in Alzheimer’s Cascade, or Just Another Player?
Scientists worldwide now perform amyloid imaging on scores of research participants to figure out how Aβ buildup relates to other markers of neurodegeneration...